BPI 501836
Alternative Names: BPI-501836Latest Information Update: 02 Jul 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Cancer in China (Intraperitoneal) prior to April 2024
- 05 Apr 2024 Preclinical trials in Cancer in China (IV) prior to April 2024
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics, adverse events data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)